ArticleScientific reports2021
Adiponectin as a novel biomarker of disease severity in alopecia areata.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications.Dermatology and therapy · 2026Article
- Metabolic syndrome and dermatological diseases: association and treatment.Nutrition & metabolism · 2025Review
- Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata.Journal of cosmetic dermatology · 2025Article
- Alopecia Areata Is Associated with an Increased Risk for Prediabetes and Obesity: A Nationwide Case-Control Study.Journal of personalized medicine · 2025Article
- Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata.Frontiers in pharmacology · 2025Article
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.Cureus · 2025Review
- Alopecia Areata Is Associated with Posttraumatic Stress Disorder and Alcohol Use in a Case-Control Study of 4,785 Patients.Skin appendage disorders · 2024Article
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata.American journal of clinical dermatology · 2024Review
- Association of Obesity and Bariatric Surgery on Hair Health.Medicina (Kaunas, Lithuania) · 2024Review
- Preliminary Report on the Influence of Acute Inflammation on Adiponectin Levels in Older Inpatients with Different Nutritional Status.International journal of molecular sciences · 2024Article
- Differential impact of environmental factors on systemic and localized autoimmunity.Frontiers in immunology · 2023Review
- Lifestyle Factors Involved in the Pathogenesis of Alopecia Areata.International journal of molecular sciences · 2022Review
- Metabolic Comorbidities in Vitiligo: A Brief Review and Report of New Data from a Single-Center Experience.International journal of molecular sciences · 2021Review
- Dietary Habits in Japanese Patients with Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021Article
- Adiponectin serum levels and ADIPOQ (rs2241766) polymorphism in alopecia areata Egyptian patients.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frequent coexistence of obesity and metabolic syndrome in patients with alopecia areata may indicate the common pathogenetic pathway in these conditions with an important role of adipokines. The aim of the study was to evaluate the serum level of adiponectin, resistin and leptin in patients with alopecia areata in comparison to healthy controls. The study included 65 patients with alopecia areata and 71 healthy controls. The concentration of adipokines was determined with the enzyme-linked immunosorbent assay. The mean concentrations of adiponectin and resistin were significantly lower in the sera of patients with alopecia areata when compared to healthy controls (7966 [Formula: see text] 4087 vs 9947 [Formula: see text] 5692 ng/ml; p = 0.0312 and 11.04 [Formula: see text] 3.88 vs 14.11 [Formula: see text] 8.69 ng/ml; p = 0.0176, respectively). A negative correlation between the serum level of adiponectin and severity of alopecia tool (SALT) score was observed (r = - 0.26; p < 0.05). The concentration of adiponectin was significantly lower in patients with alopecia universalis than in patients with patchy alopecia areata (4951 [Formula: see text] 2499 vs 8525 [Formula: see text] 4085 ng/ml; p = 0.0135). No significant difference in the serum concentration of leptin was observed between patients with alopecia areata and healthy controls. The negative correlation between the serum level of adiponectin and hair loss severity indicates that adiponectin may be considered a marker of hair loss severity in alopecia areata. Further studies are needed to evaluate the role of resistin in patients with alopecia areata and its decreased level irregardless of severity or activity of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.